Intervacc AB (publ) (STO:IVACC)

Market Cap	311.84M +345.1%
Revenue (ttm)	21.09M +127.1%
Net Income	-63.31M
EPS	-0.27
Shares Out	340.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	221,793
Average Volume	261,338
Open	0.8700
Previous Close	0.8620
Day's Range	0.8500 - 0.9190
52-Week Range	0.7510 - 1.3520
Beta	0.47
RSI	53.59
Earnings Date	Feb 16, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 15
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2024, Intervacc AB's revenue was 11.79 million, an increase of 46.84% compared to the previous year's 8.03 million. Losses were -75.52 million, -26.58% less than in 2023.